Myeloma Minute: Why Prevention Matters
|
| INNOVATION | Latest Research
Why Prevention MattersCuring multiple myeloma is a goal we all share. The IMF’s Black Swan Research Initiative® is engaged in dozens of studies around the world aimed at just that. But in the meantime, more and more research suggests we might prevent myeloma by limiting our exposure to cancer-triggering toxins.
|
|
|
| Action | Baseball for Myeloma
Multiple Myeloma Survivor to Throw Out First Pitch at Sept. 16 Houston Astros GameMichael Tuohy, an eighteen-year myeloma survivor, will throw the ceremonial first pitch at the Houston Astros baseball game on September 16. Michael will represent the International Myeloma Foundation (IMF), the first and largest foundation focusing specifically on multiple myeloma. Sponsored by Amgen Oncology, this game at Houston’s Minute Maid Park will raise awareness of myeloma and encourage patients to create a personal treatment management strategy. Through its newly launched Myeloma MVP (Most Valuable Plan) program, Amgen is connecting myeloma patients with management guidance tools and educational resources, including the comprehensive IMF website.
|
|
|
| INSPIRATION | Fundraiser
|
| EDUCATION | Event
|
Sixth Annual Miracles for Myeloma 5K Race/Walk |
Register NOW for a Regional Community Workshop in Birmingham, Alabama |
|
The Sixth Annual Miracles for Myeloma 5K Race/Walk takes place on Saturday, September 22, 2018, beginning at 9:30 a.m. EST on a USATF-certified course in Oak Ridge Park, New Jersey. Registration ends on September 18 at midnight. Donations can be made until December, whether or not you are able to participate. Last year’s Miracles for Myeloma raised nearly $80,000 for myeloma research, funding a Senior Brian D. Novis Research Grant. Once again, we encourage you to help raise myeloma awareness and funds as we work toward a cure. |
The IMF will conduct a Regional Community Workshop in Birmingham, AL, on Saturday, October 6, 2018. Registration is FREE, but seating is limited. This is a wonderful opportunity to learn from and meet one-on-one with myeloma experts Luciano J. Costa, MD, PhD (Associate Professor of Medicine, University of Alabama at Birmingham), Kelly Godby, MD (Assistant Professor of Medicine, UAB Hematology/Oncology, University of Alabama at Birmingham), and Charise Gleason, MSN, NP-BC, AOCNP (Winship Cancer Institute, Emory University, Atlanta). |
|
|
|
|
| INNOVATION | Drug Development
Empliciti (elotuzumab) Drug Combination Granted Priority Review by FDABristol-Myers Squibb has announced that the FDA accepted its supplemental Biologics License Application (sBLA) for Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma who have received at least two prior therapies, including Revlimid (lenalidomide) and a proteasome inhibitor. The FDA granted the application priority review with an action date of December 27, 2018. This sBLA was submitted based on the phase II ELOQUENT-3 trial.
|
|
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series
|
|
CLINICAL TRIALS |
EVENTS |
|
New isatuximab Clinical Trial: the IMROZ Study New isatuximab Clinical Trial: the IKEMA Study New ixazomib Clinical Trials: Learn How to Participate Join the conversation about myeloma on the Smart Patients Message Board |
September 8, 2018 September 15, 2018 September 22, 2018 September 22, 2018 September 22, 2018 October 12-13, 2018 |
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year